Regeneron Pharmaceuticals (NQ:REGN)

728.01 -7.19 (-0.98%)

Delayed Quote Updated: 2:54 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

66 67 Next >

2 Healthcare Stocks with Big Upside and 1 to Skip

February 21, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 20, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

This Company Just Initiated a Quarterly Dividend: Time to Buy? ↗

February 18, 2025

Via The Motley Fool

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

February 17, 2025

Via Benzinga

Biogen Stock Is Mutating Into a Value Play

February 20, 2025

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Via MarketBeat

REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

February 18, 2025

From Robbins LLP

Via GlobeNewswire

Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

February 18, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

February 14, 2025

Via Benzinga

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 14, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Discover the top S&P500 movers in Wednesday's pre-market session. ↗

February 12, 2025

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 11, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

February 11, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

How Databricks Pounced On AI Opportunity Amid Snowflake, Palantir Rivalries ↗

February 11, 2025

The rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative artificial intelligence.

Via Investor's Business Daily

Topics Artificial Intelligence

Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma

February 11, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Healthcare And Biotech Playbook As Disruption Gathers Force ↗

February 10, 2025

The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.

Via Talk Markets

Topics ETFs Stocks / Equities

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study ↗

February 10, 2025

4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Via Benzinga

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

February 09, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.

Via StockStory

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting

February 08, 2025

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4...

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

February 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 8 ↗

February 08, 2025

What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 3-7, 2025.

Via Talk Markets

Topics Stocks / Equities

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗

February 07, 2025

Via Benzinga

Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page ↗

February 06, 2025

The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug.

Via Stocktwits

Billions in Buybacks: 4 Stocks Rewarding Shareholders Now

February 06, 2025

These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.

Via MarketBeat

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

February 05, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗

February 04, 2025

Via The Motley Fool

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

66 67 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.